PURPOSE: To explore the impact of UDP-glucuronosyltransferase polymorphisms (UGT1A9-118(dT) 9/10 , UGT1A9 CI399T, UGT1A9 C-440T and UGT2B7 G211T) on the pharmacokinetics of mycophenolic acid (MPA) in healthy Chinese volunteers. METHODS: We recruited ten healthy volunteers with no polymorphisms (control group), 11 homozygotes of mutants UGT1A9 CI399T and UGT1A9-118(dT) 9/10 , ten heterozygotes of UGT1A9 C440T and seven carriers of UGT2B7 211T from a total of 518 healthy Chinese volunteers. All the volunteers were orally administered a single dose of 1.5 g mycophenolate mofetil (MMF) after an overnight fast. Plasma was then collected 72 h after MMF administration. MPA, MPA-7-O-glucuronide (MPAG) and its acylglucuronide (AcMPAG) were detected by ultra-pressure liquid chromatography with UV detection. RESULTS: Compared with the control group, the UGT1A9 CI399T and UGT1A9-118(dT) 9/10 mutant homozygotes had higher MPAG plasma concentrations. Subjects with UGT1A9-440TC had enhanced MPA exposure while carriers of UGT2B7 211T had higher concentrations of the toxic metabolite, AcMPAG. CONCLUSIONS: The current results indicate that UGT1A9 and UGT2B7 genotypes could significantly alter MPA pharmacokinetics in healthy Chinese volunteers after a single oral dose of MMF.
PURPOSE: To explore the impact of UDP-glucuronosyltransferase polymorphisms (UGT1A9-118(dT) 9/10 , UGT1A9 CI399T, UGT1A9C-440T and UGT2B7G211T) on the pharmacokinetics of mycophenolic acid (MPA) in healthy Chinese volunteers. METHODS: We recruited ten healthy volunteers with no polymorphisms (control group), 11 homozygotes of mutants UGT1A9 CI399T and UGT1A9-118(dT) 9/10 , ten heterozygotes of UGT1A9C440T and seven carriers of UGT2B7 211T from a total of 518 healthy Chinese volunteers. All the volunteers were orally administered a single dose of 1.5 g mycophenolate mofetil (MMF) after an overnight fast. Plasma was then collected 72 h after MMF administration. MPA, MPA-7-O-glucuronide (MPAG) and its acylglucuronide (AcMPAG) were detected by ultra-pressure liquid chromatography with UV detection. RESULTS: Compared with the control group, the UGT1A9 CI399T and UGT1A9-118(dT) 9/10 mutant homozygotes had higher MPAG plasma concentrations. Subjects with UGT1A9-440TC had enhanced MPA exposure while carriers of UGT2B7 211T had higher concentrations of the toxic metabolite, AcMPAG. CONCLUSIONS: The current results indicate that UGT1A9 and UGT2B7 genotypes could significantly alter MPA pharmacokinetics in healthy Chinese volunteers after a single oral dose of MMF.
Authors: M Shipkova; E Wieland; E Schütz; C Wiese; P D Niedmann; M Oellerich; V W Armstrong Journal: Transplant Proc Date: 2001 Feb-Mar Impact factor: 1.066
Authors: Teun van Gelder; Yann Le Meur; Leslie M Shaw; Michael Oellerich; David DeNofrio; Curtis Holt; David W Holt; Bruce Kaplan; Dirk Kuypers; Bruno Meiser; Burkhard Toenshoff; Richard D Mamelok Journal: Ther Drug Monit Date: 2006-04 Impact factor: 3.681
Authors: Richard Borrows; Gary Chusney; Anthony James; Jose Stichbury; Jen Van Tromp; Tom Cairns; Megan Griffith; Nadey Hakim; Adam McLean; Andrew Palmer; Vassilios Papalois; David Taube Journal: Ther Drug Monit Date: 2005-08 Impact factor: 3.681
Authors: M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq Journal: Clin Chem Date: 2001-01 Impact factor: 8.327
Authors: Hugo Girard; Lyne Villeneuve; Michael H Court; Louis-Charles Fortier; Patrick Caron; Qin Hao; Lisa L von Moltke; David J Greenblatt; Chantal Guillemette Journal: Drug Metab Dispos Date: 2006-04-04 Impact factor: 3.922
Authors: A I Sánchez-Fructuoso; M L Maestro; N Calvo; M Viudarreta; I Pérez-Flores; S Veganzone; V De la Orden; D Ortega; M Arroyo; A Barrientos Journal: Transplant Proc Date: 2009 Jul-Aug Impact factor: 1.066
Authors: Vishal Lamba; Katrin Sangkuhl; Kinjal Sanghavi; Alyssa Fish; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2014-01 Impact factor: 2.089